Engineered immune cells take on childhood leukemia in early trial
NCT ID NCT01683279
First seen Jun 12, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This early-stage study tests a new treatment for children and young adults with relapsed B-cell leukemia. The approach uses a patient's own immune cells, modified to recognize and attack leukemia cells. The main goals are to check safety and find the best dose, with a secondary look at whether the cells can clear the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.